
- /
- Supported exchanges
- / F
- / G0FB.F
Grifols S.A (G0FB F) stock market data APIs
Grifols S.A Financial Data Overview
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag that are in LCM stage; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL which are in regulatory stage; Prolastin-C AADT and Fostamatinib that are in Phase IV; Xembify " CLL, Albumina 20% and 5%, and Trimodulin which are in Phase III; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290 that are in Phase II; GIGA 2339 and GIGA564 which are in Phase I; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Grifols S.A data using free add-ons & libraries
Get Grifols S.A Fundamental Data
Grifols S.A Fundamental data includes:
- Net Revenue: 7 212 M
- EBITDA: 1 608 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Grifols S.A News

High Growth Tech Stocks in Europe for March 2025
As European markets face uncertainty due to U.S. trade policy and recent ECB rate cuts, the pan-European STOXX Europe 600 Index has snapped a 10-week streak of gains, although increased defense and in...


Is Grifols, S.A. (GRFS) the Best Low Price Pharma Stock to Invest In Right Now?
We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now.In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pha...

Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic ...
Release Date: February 26, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Grifols SA (GIFLF) achieved record revenues and ...

Exploring High Growth Tech Stocks In February 2025
As global markets navigate a volatile start to 2025, with the Federal Reserve holding rates steady and AI competition shaking up the tech sector, investors are closely watching how these dynamics impa...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.